2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
2019 update to : Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). / Buse, John B.; Wexler, Deborah J.; Tsapas, Apostolos; Rossing, Peter; Mingrone, Geltrude; Mathieu, Chantal; D'Alessio, David A.; Davies, Melanie J.
I: Diabetes Care, Bind 43, Nr. 2, 2020, s. 487-493.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - 2019 update to
T2 - Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
AU - Buse, John B.
AU - Wexler, Deborah J.
AU - Tsapas, Apostolos
AU - Rossing, Peter
AU - Mingrone, Geltrude
AU - Mathieu, Chantal
AU - D'Alessio, David A.
AU - Davies, Melanie J.
PY - 2020
Y1 - 2020
N2 - The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals witha glucagon-like peptide1 (GLP-1) receptor agonist or sodium-glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can alsobeconsidered in patients with type 2 diabetes without established cardiovascular disease (CVD) but withthe presence of specific indicators of high risk; and 3)SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min-1 [1.73 m]2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.
AB - The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals witha glucagon-like peptide1 (GLP-1) receptor agonist or sodium-glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can alsobeconsidered in patients with type 2 diabetes without established cardiovascular disease (CVD) but withthe presence of specific indicators of high risk; and 3)SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min-1 [1.73 m]2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.
U2 - 10.2337/dci19-0066
DO - 10.2337/dci19-0066
M3 - Journal article
C2 - 31857443
AN - SCOPUS:85078384213
VL - 43
SP - 487
EP - 493
JO - Diabetes Care
JF - Diabetes Care
SN - 0149-5992
IS - 2
ER -
ID: 255886692